How Dr. Gates Monitors Every Patient on GLP-1s

One of the most important differences between safe, effective GLP-1 therapy and a potentially risky experience is not the medication itself — it is the quality of monitoring behind it. GLP-1 receptor agonists like semaglutide (Wegovy, Ozempic), tirzepatide (Zepbound, Mounjaro), and liraglutide (Saxenda) are powerful, well-studied medications. But they are also prescription drugs that require individualized evaluation, careful dose titration, and ongoing clinical follow-up. At Scale Solutions in Savannah, Pooler, and Hinesville GA, Dr. Donald L. Gates MD has built a structured monitoring protocol for every GLP-1 patient — one that reflects more than 25 years of bariatric medicine experience and the most current evidence-based guidelines.

This article describes exactly what that monitoring involves: what tests are ordered, when, and why. Understanding the protocol helps patients appreciate why physician-supervised GLP-1 therapy is fundamentally different from an online subscription service — and why that difference matters for safety and outcomes.

Why Monitoring Matters: What Can Change on GLP-1 Therapy

GLP-1 medications do not simply reduce appetite. They affect multiple organ systems: the pancreas (insulin and glucagon secretion), the gastrointestinal tract (motility and absorption), the cardiovascular system (heart rate, blood pressure, lipid metabolism), the kidneys (filtration and urine protein excretion), and thyroid tissue (as addressed in our black-box warning article). In patients with pre-existing diabetes, blood sugar levels and HbA1c can change significantly during treatment, often requiring adjustment of other diabetes medications to prevent hypoglycemia.

Weight loss itself — even beneficial weight loss — creates physiological changes that require monitoring: blood pressure may fall, lipid levels shift, liver enzymes may improve, and nutritional adequacy must be assessed. Monitoring is not bureaucratic box-checking; it is the clinical mechanism through which benefits are documented, risks are caught early, and the treatment plan is continuously optimized.

The Baseline Evaluation: Before the First Dose

No patient at Scale Solutions receives a GLP-1 prescription without a thorough baseline evaluation. This begins with a comprehensive clinical interview covering:

• Personal and family history of medullary thyroid carcinoma, Multiple Endocrine Neoplasia type 2, pancreatitis, and gallbladder disease
• Current medications — particularly diabetes medications (insulin, sulfonylureas) that carry hypoglycemia risk when combined with GLP-1 therapy
• Cardiovascular history: prior heart attack, stroke, arrhythmias, heart failure
• Gastrointestinal history: gastroparesis, inflammatory bowel disease, prior GI surgery
• Kidney and liver function history
• Current weight, height, BMI calculation, and body composition assessment
• Blood pressure measured in the office

Baseline Laboratory Panel

A comprehensive baseline laboratory panel is ordered before initiating therapy. This typically includes:

• Complete metabolic panel (CMP): Assesses liver enzymes (AST, ALT), kidney function (creatinine, BUN, eGFR), electrolytes, and glucose
• HbA1c: Establishes baseline glycemic status; essential for monitoring glucose changes and adjusting diabetes medications
• Fasting lipid panel: Baseline LDL, HDL, triglycerides, and total cholesterol for cardiovascular risk assessment and to track improvement
• Thyroid-stimulating hormone (TSH): To rule out undiagnosed thyroid disease before starting a medication with a thyroid C-cell warning
• Complete blood count (CBC): Assesses overall health and nutritional status
• Vitamin B12, folate, iron studies: Particularly important in patients with dietary restrictions or prior GI surgery, as GLP-1-induced reduced appetite can compromise micronutrient intake
• Urine albumin-to-creatinine ratio (uACR): Screens for diabetic nephropathy and establishes kidney health baseline, especially relevant given the FLOW trial’s kidney protection data
• Serum calcitonin: Considered on an individualized basis for patients with thyroid risk factors or family history of thyroid cancer

The Titration Phase: Weeks 1–20

The FDA-approved dose escalation schedule for semaglutide begins at 0.25 mg weekly and increases every four weeks: 0.5 mg, 1.0 mg, 1.7 mg, and finally 2.4 mg for the maintenance phase. Tirzepatide has a comparable escalation structure. This slow titration period is the highest-risk time for gastrointestinal side effects, and it is when most patients benefit most from close clinical support.

During the titration phase, Dr. Gates schedules check-in visits or telehealth consultations to:

• Assess tolerance of the current dose — nausea severity, appetite changes, GI symptoms
• Review weight change and adjust diet and activity guidance accordingly
• Monitor blood pressure, which may begin falling with early weight loss
• Evaluate the need for dose holds or slower escalation in patients with significant GI side effects
• Adjust concomitant diabetes medications if blood sugar trends downward in diabetic patients
• Screen for any serious symptoms — severe abdominal pain, vision changes, neck masses — that warrant urgent evaluation

This phase-specific attention is critical. The Endocrine Society’s clinical practice guidelines for obesity pharmacotherapy emphasize that dose titration should be individualized based on tolerability, and that slower escalation is appropriate for patients who experience significant side effects. A patient who is not being seen or contacted during titration is not receiving guideline-consistent care.

Ongoing Monitoring at the Maintenance Dose

Once patients reach the maintenance dose and stabilize, monitoring frequency adjusts — but it does not stop. At Scale Solutions, patients on stable GLP-1 therapy are typically seen at regular intervals that allow for:

Laboratory Follow-Up

• HbA1c every 3–6 months in diabetic patients during the first year; annually once stable. GLP-1 therapy consistently reduces HbA1c and may allow reduction of other diabetes medications — missing this opportunity leaves patients on unnecessary medications with their own risks.
• CMP (kidney function and liver enzymes) at regular intervals, typically every 3–6 months initially. The FLOW trial demonstrated kidney protection with semaglutide; monitoring eGFR and urine albumin tracks both safety and treatment benefit.
• Fasting lipid panel annually or more frequently if values were abnormal at baseline. GLP-1 therapy improves lipid profiles in most patients, and medication adjustments may be indicated.
• TSH annually in all patients; more frequently if thyroid symptoms develop.
• Vitamin and nutritional panels periodically, particularly in patients with significant food restriction or symptoms of deficiency.

Clinical Assessment

• Weight and BMI: Tracked at every visit to assess treatment response and set targets
• Blood pressure: Monitored at every visit; antihypertensive medications may need to be reduced as weight decreases
• Symptom review: Ongoing assessment for GI symptoms, injection site reactions, any new or concerning symptoms
• Cardiovascular review: Chest pain, dyspnea, palpitations, edema — particularly relevant in patients with established cardiovascular disease
• Mental health screening: Weight and self-image are closely linked; Dr. Gates screens for mood changes, which are relevant given the importance of behavioral support in sustained weight management

Monitoring Safety Events: What to Watch For and When to Act

Dr. Gates provides all Scale Solutions patients with explicit guidance on which symptoms to monitor at home between visits and which require prompt contact. The key thresholds are:

• Severe upper abdominal pain — call immediately or go to the ER to rule out pancreatitis
• Neck lump, hoarseness, or difficulty swallowing — call promptly for thyroid evaluation
• Signs of hypoglycemia in diabetic patients (shakiness, sweating, confusion) — call immediately; may require medication adjustment
• Inability to tolerate fluids — dehydration risk requiring evaluation
• Significant injection site reactions — allergic reactions are rare but serious
• New or worsening vision problems — may indicate diabetic retinopathy changes

This patient education component of the monitoring protocol is often overlooked but is equally important to the scheduled visits. A patient who knows what to watch for and how to reach their physician is fundamentally safer than one who does not.

How Scale Solutions Monitoring Compares to Online Services

The proliferation of online and telehealth GLP-1 prescription services has made access to these medications easier — but it has also created a landscape where some patients receive prescriptions with minimal or no baseline laboratory evaluation, no in-person weight and blood pressure monitoring, and no systematic follow-up protocol. The FDA’s concerns about compounded and online GLP-1 sources partly reflect this monitoring deficit.

At Scale Solutions, Dr. Gates is physically present for examinations, personally reviews laboratory results, and makes individualized clinical decisions based on the full clinical picture — not a digital questionnaire. This is the standard of care that the evidence supports, and it is why the large clinical trials showing GLP-1 safety and efficacy were conducted in physician-supervised settings with rigorous monitoring protocols.

Coordination with Other Specialists

Many Scale Solutions patients have multiple physicians managing different aspects of their health — cardiologists, endocrinologists, primary care physicians, nephrologists. Dr. Gates coordinates with these specialists, communicating GLP-1 initiation, dose changes, and relevant laboratory findings. This coordination ensures that, for example, a cardiologist is aware that semaglutide has been started and that blood pressure medications may need to be adjusted as weight and BP decline — or that a nephrologist is tracking kidney function changes in the context of GLP-1’s renal protective effects as demonstrated in the FLOW trial. Visit our coastal Georgia GLP-1 news page for updates on emerging evidence and practice guidelines.

Schedule Your Monitored GLP-1 Consultation

Dr. Donald L. Gates MD brings Loma Linda-trained bariatric medicine expertise and over 25 years of clinical experience to every patient evaluation at Scale Solutions. His comprehensive monitoring protocol — from baseline labs through ongoing follow-up — is what makes GLP-1 therapy safe and effective for the patients he serves throughout Savannah, Pooler, and Hinesville GA. To schedule your consultation, call (912) 352-7546 or email info@scale-solutions.com.

Medical Disclaimer: This article describes general monitoring principles used in GLP-1 therapy; individual patient protocols vary based on medical history, comorbidities, and clinical judgment. This content is for informational purposes only and does not constitute medical advice. Always consult a licensed physician for guidance on your personal health care. GLP-1 medications require a valid physician prescription and should not be used without medical supervision.

Frequently Asked Questions

How often will I need lab tests while on a GLP-1 medication?

Lab testing frequency depends on your individual health status. Typically, baseline labs are drawn before starting therapy, and follow-up panels — including kidney function, HbA1c, and lipids — are repeated at 3 to 6 month intervals during the first year, then annually once values are stable. Patients with diabetes, kidney disease, or cardiovascular conditions may be monitored more frequently. Dr. Gates individualizes this schedule based on your clinical picture at each visit.

Do I need to monitor my blood pressure at home while on semaglutide?

Home blood pressure monitoring is strongly encouraged, particularly for patients who start GLP-1 therapy with hypertension or who are on antihypertensive medications. Blood pressure often falls meaningfully as weight decreases, and antihypertensive doses may need to be reduced to avoid hypotension. Dr. Gates reviews blood pressure at every visit and provides guidance on what readings should prompt a call to the office.

What happens if my labs show a problem while I am on a GLP-1?

If laboratory results show a concerning change — such as rising creatinine, worsening liver enzymes, or significantly elevated calcitonin — Dr. Gates will contact you directly, interpret the finding in the context of your full clinical history, and determine the appropriate next step. This may range from repeating the test to adjusting the dose to pausing therapy and pursuing further evaluation. The structured monitoring protocol exists precisely to catch these changes early, when they are most treatable.

Does Dr. Gates adjust my other medications when I start a GLP-1?

Yes, and this is one of the most clinically important aspects of physician supervision. Patients on insulin or sulfonylureas for diabetes are at risk for hypoglycemia as GLP-1 therapy improves blood sugar control — doses often need to be reduced proactively. Patients on antihypertensive medications may need dose reductions as blood pressure falls with weight loss. Dr. Gates reviews all concomitant medications at each visit and makes adjustments based on how your body is responding to treatment.

What if I cannot come into the office — does Scale Solutions offer telehealth?

Scale Solutions serves patients across the coastal Georgia region and offers flexible scheduling at offices in Savannah, Pooler, and Hinesville. For routine check-ins during stable therapy, telehealth options may be available depending on the clinical situation. However, certain visits — particularly the baseline evaluation and any visit prompted by new symptoms — require in-person assessment. Please call (912) 352-7546 to discuss scheduling options that work for your situation.